JIA with Non-Systemic Polyarthritis (≥5 Joints): What to Do After a Second Biologic Fails

This protocol applies to children with juvenile idiopathic arthritis and non-systemic polyarthritis — five or more joints ever involved — in whom the second biologic agent did not achieve low disease activity and a further treatment step is required.

Clinical Scenario

JIA with polyarthritis (≥5 joints ever involved), excluding systemic arthritis and sacroiliitis. This group may include children across different ILAR JIA categories who share widespread joint involvement without systemic or axial features.

Previous Treatment & Unmet Target

The preceding step involved switching to a non-TNFi biologic (tocilizumab or abatacept) — or, for patients with secondary failure of a first TNFi, a second TNFi. That treatment did not achieve the required target: low disease activity (clinical JADAS-10 ≤2.5). This protocol defines the appropriate next step following that failure.

Next Treatment Approach

The evidence-based approach for this situation involves choosing among a defined set of biologic options selected according to the biologics already received, with a specific class conditionally preferred over another. The complete selection logic, treatment target, and full regimen are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/acr.23870

This group includes children with JIA and polyarthritis (≥5 joints ever involved) and may include children from different ILAR JIA categories but excludes children with systemic arthritis or sacroiliitis.

In patients with JIA and polyarthritis and moderate or high disease activity despite a second biologic, using a TNFi, abatacept, or tocilizumab (depending upon prior biologics received) is conditionally recommended over rituximab.

Good disease control, with therapeutic escalation to achieve low disease activity, was recommended.

View source ↗